Becton, Dickinson and Company $BDX Stock Holdings Increased by Allstate Corp

Key Points

• Allstate Corp doubled its stake in Becton, Dickinson and Company during the fourth quarter, increasing holdings by 101.6% to 21,123 shares worth about $4.1 million.
• BDX reported better-than-expected quarterly results, posting EPS of $2.90 versus the $2.77 estimate and revenue of $4.71 billion, with sales up 5.2% year over year.
• The company also declared a quarterly dividend of $1.05 per share, representing an annualized yield of 2.8%, while analysts currently rate the stock a consensus Hold with a $184.86 target price.

Allstate Corp raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 101.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,123 shares of the medical instruments supplier's stock after acquiring an additional 10,647 shares during the period. Allstate Corp's holdings in Becton, Dickinson and Company were worth $4,099,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Activest Wealth Management raised its stake in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $25,000. Steph & Co. increased its position in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 65 shares during the period. Cornerstone Planning Group LLC increased its position in shares of Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 139 shares during the period. Finally, Accredited Wealth Management LLC increased its position in shares of Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 70 shares during the period. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

BDX opened at $147.38 on Thursday. The stock has a market cap of $40.61 billion, a price-to-earnings ratio of 37.31, a PEG ratio of 10.46 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a fifty day moving average price of $152.11 and a 200 day moving average price of $177.44.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion during the quarter, compared to analysts' expectations of $4.67 billion. During the same quarter last year, the firm earned $3.35 earnings per share. The business's revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.8%. Becton, Dickinson and Company's dividend payout ratio is 106.33%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BDX shares. Argus dropped their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating on the stock in a research report on Monday, March 23rd. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Barclays lifted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a report on Monday, May 11th. Wells Fargo & Company lifted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an "equal weight" rating in a report on Friday, May 8th. Finally, Evercore lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $184.86.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.